Apg-2575
Lisaftoclax
M.D. Anderson Cancer CenterPhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Lisaftoclax cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid M.D. Anderson Cancer Center | Phase 2/3 | B |
Daunorubicin First Affiliated Hospital of Zhejiang University | Phase 2/3 | B |
Omacetaxine First Affiliated Hospital of Zhejiang University | Phase 2/3 | B |
Azacitidine First Affiliated Hospital of Zhejiang University | Phase 2/3 | B |
Aclarubicin First Affiliated Hospital of Zhejiang University | Phase 2/3 | B |
FILGRASTIM M.D. Anderson Cancer Center | Phase 1 | CC |
Pelcitoclax M.D. Anderson Cancer Center | Phase 1 | CC |
Fludarabine M.D. Anderson Cancer Center | Phase 1 | CC |
Same molecule, other indications
Apg-2575 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →